CATEGORY: Feed Additives
AUTHORS: Araujo, G., Bach, A., Mereu, A. and Ipharraguerre, I.R.
BOOK/JOURNAL:XV Jornadas sobre Producción Animal, Zaragoza 14 y 15 de mayo de 2013 pp. 300-302
Butyrate in the form of sodium butyrate (SB) is often used as an additive for milk replacers (MR) to improve calf and piglet performance. Tributyrin (TRB) is a triglyceride containing equivalent amounts of butyrate than SB but in a more stable form. Thirty-six Holstein calves (45.7±5.9 kg of BW and 11.9±3.0 d of age) were fed 4 L/d of MR and water and starter feed ad libitum. Calves were randomly distributed in 2 groups. Milk replacer was either unsupplemented (CTR) or supplemented with 3 g of tributyrin per kg of DM (TRB). Five calves per group were restricted at 200 g/d of starter and these calves were subjected to glucose tolerance tests (GTT) to assess resistance on days 0 and 42 of study. Calves were blood-sampled every 14 d for glucose, insulin, GLP-1 and BHBA before and 60 min after the morning MR offer. Calves in the CTR group showed better performance parameters. No differences were found in plasma GLP-1, BHBA, insulin, and glucose between treatments. However, evolution of plasma BHBA along time tended to differ (P<0.08) because on day 14, plasma BHBA concentration before and after MR feeding was similar for TRB calves while CTR calves tended (P=0.06) to have a lesser concentration after MR. Evolution of plasma glucose and insulin across time also differed (P<0.001 and P<0.001, respectively) between treatments. Plasma glucose after morning MR take increased later (P<0.05) in time in TRB than in CTR calves; but CTR calves had greater (P<0.05) insulin levels on day 14 than 28. Results from the GTT showed that glucose peak and GCR on day 42 were greater (P<0.05) for TRB than for C calves (3.5 vs 5.8±0.69 mmol/L and 4.6 vs 17.3±3.09 mmol/Lxmin; respectively) which indicates a different insulin secretion pattern between treatments. In conclusion, these results demonstrate that butyrate supplementation in the form of tributyrin at 3 g/kg of MR modulates glucose and insulin hemodynamic but does not alter BHBA and GLP-1 plasma concentration nor increases performance.